Navigating the Future of CDXs in Oncology
Clips
CDX expert Dawn McHugh joins Dr. Rebecca Previs to unpack the role of companion diagnostics in precision oncology and the future of cancer care.
How are companion diagnostics (CDXs) transforming the landscape of precision oncology? In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs welcomes CDX expert Dawn McHugh, Director of Precision Oncology CDx at Labcorp, for a deep dive into the evolving world of companion diagnostics.
You’ll learn what defines a true CDX, how it differs from other biomarker tests, and why integrating it with targeted therapies is essential for matching the right patient to the right treatment. Dawn McHugh guides us through real-world examples—from HER2 and EGFR to the latest in liquid biopsy—explaining how these diagnostics are expanding access, shaping new therapies, and accelerating the pace of cancer innovation. The conversation explores development timelines, regulatory hurdles, the value of early collaboration, and emerging technologies like AI and decentralized NGS.
Whether you’re an oncologist, researcher, or pharma partner, this episode delivers actionable insights on the present and future impact of CDXs in oncology care.
Tune in for a dynamic, forward-looking discussion and gain a new perspective on the science fueling tomorrow’s breakthroughs.